A single, one-time infusion of onasemnogene abeparvovec-xioi (Zolgensma) can minimize the progression of SMA and improve survival in children younger than age 2 years — and will cost over $2 million. FDA Approvals
Researchers compared robot-assisted upper limb training vs enhanced therapy or standard care in patients recovering from stroke, and find no advantage for the robotic assist. Medscape Medical News
The absolute risk for ischemic stroke was consistently higher than the absolute risk for ICH regardless of microbleed burden, a new pooled analysis found. Medscape Medical News
Restarting antiplatelet therapy after intracranial hemorrhage remains controversial, but new evidence suggests aspirin or clopidogrel can significantly reduce recurrent ICH without increased bleeding. Medscape Medical News
Further results have confirmed the benefit of thrombolysis up to 9 hours after onset of ischemic stroke in patients with salvageable brain tissue identified by mismatch on CT perfusion imaging. Medscape Medical News
A new prospective study of this rare but severe complication finds female sex, older age, and history of kidney disease ups the risk. Medscape Medical News
As mounting research shows that the practice of ‘reprocessing’ spinal surgery screws leads to contamination, some countries are outlawing them, but the US appears to be foot-dragging. Medscape Medical News
Out-of-pocket costs for drugs used to treat neurologic diseases have increased sharply over the past 13 years, including a 20-fold increase for MS medications. Medscape Medical News
Nayzilam is the first FDA-approved nasal option for treating seizure clusters that are distinct from a patient’s usual seizure pattern in patients aged 12 years or older. FDA Approvals
Nayzilam is the first FDA-approved nasal option for treating seizure clusters that are distinct from a patient’s usual seizure pattern in patients aged 12 years or older. FDA Approvals
Measuring wall strain of the heart appears to be a good prognostic indicator of brain injury in patients with subarachnoid hemorrhage, a new study shows. Medscape Medical News
A study of nearly 450 people with atrial fibrillation (AF) treated in the emergency department suggests that anticoagulants may be ‘vastly underutilized’ for the prevention of stroke. Medscape Medical News
A recent study suggests that light physical activity may help stave off signs of aging in the brain. Reuters Health Information
The antiplatelet agent has bactericidal activity against multidrug-resistant gram-positive bacteria and may represent a new class of antibiotic, new research suggests. Medscape Medical News
The novel self-administered subcutaneous agent is safe and relatively well tolerated in generalized myasthenia gravis, a new phase 2 trial and extension study report. Medscape Medical News
Further data from the phase 2 trial of show a significant reduction in enhancing MRI lesions with one of the doses tested but increases in liver enzymes may be an issue. Medscape Medical News
A real-world study shows a doubling of survival in patients with severe traumatic brain injury who receive prehospital guideline-based care by paramedics. Medscape Medical News
The FDA has approved broadening the indication for incobotulinumbtoxinA as first-line therapy for blepharospasm, based on a phase 3 trial presented at the recent American Academy of Neurology meeting. FDA Approvals
An experimental agent promises to improve the lives of patients with Angelman syndrome, a rare genetic disorder for which there are no approved therapies and that carries a high, unmet medical need. Medscape Medical News
IncobotulinumtoxinA is indicated for patients with blepharospasm who previously received onabotulinumtoxinA — but a new phase 3 study suggests it’s also effective as first-line therapy. Medscape Medical News
Copyright © 2019 | WordPress Theme by MH Themes
